Comparing vaccines: A systematic review of the use of the non-inferiority margin in vaccine trials

Vaccine

Volumn 33, Issue 12, 2015, Pages 1426-1432

  Donken, R ^a,b   de Melker, H E ^a   Rots, N Y ^a   Berbers, G ^a   Knol, M J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Non inferiority margin; Trials; Vaccine

Indexed keywords

VACCINE;

ATTRIBUTABLE RISK; COCHRANE LIBRARY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; VACCINATION; EPIDEMIOLOGY; STATISTICS AND NUMERICAL DATA;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROEPIDEMIOLOGIC STUDIES; VACCINES;

EID: 84924519573     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.072     Document Type: Review

References (17)

1. Wangge G., Klungel O.H., Roes K.C., de Boer A., Hoes A.W., Knol M.J. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE 2010, 5(10):pe13550.
2. FDA Guidance for industry; non-inferiority clinical trials. US Dept of Health and Human Service 2010, http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm202140.pdf.
3. Rothmann M., Wiens B., Chan I. Design and analysis of non-inferiority trials 2012, Chapman & Hall, London.
4. Soonawala D., Dekkers O.M. 'Non-inferiority' trials. Tips for the critical reader. Research methodology 3. Ned Tijdschr Geneeskd 2012, 156(19):A4665.
5. CHMP Note for guidance on the clinical evaluation of new vaccines. CHMP 1999, London, CPMP/EWP/463/97.
6. CHMP Note for guidance of the clinical evaluation of vaccines. CHMP 2005, London, EMEA/CHMP/EWP/5872/03.
7. Schiller P., Burchardi N., Niestroj M., Kieser M. Quality of reporting of clinical non-inferiority and equivalence randomised trials-update and extension. Trials 2012, 13:p214.
8. Rijksinstituut voor Volksgezondheid en Milieu Meldingsplichtige Infectieziekten 2013, Rijksinstituut voor Volksgezondheid en Milieu. http://www.rivm.nl/Onderwerpen/M/Meldingsplicht_infectieziekten/Welke_infectieziekten_zijn_meldingsplichtig.
9. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003, 22(2):169-186.
10. Wang W.W., Mehrotra D.V., Chan I.S., Heyse J.F. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006, 16(4):429-441.
11. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006, 295(10):1152-1160.
12. Piaggio G., Elbourne D.R., Pocock S.J., Evans S.J., Altman D.G. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012, 308(24):2594-2604.
13. Hernandez A.V., Pasupuleti V., Deshpande A., Thota P., Collins J.A., Vidal J.E. Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review. PLoS ONE 2013, 8(5):e63272.
14. Soonawala D., Middelburg R.A., Egger M., Vandenbroucke J.P., Dekkers O.M. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. Int J Epidemiol 2010, 39(6):1567-1581.
15. Saad E.D., Buyse M. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. Acta Oncol 2012, 51(7):890-896.
16. Rising K., Bacchetti P., Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008, 5(11):e217. discussion e217.
17. Liberati A., D'Amico R. Commentary: The debate on non-inferiority trials: 'when meta-analysis alone is not helpful'. Int J Epidemiol 2010, 39(6):1582-1583.